C N Black1, M Bot1, P G Scheffer2, B W J H Penninx1. 1. Department of Psychiatry and EMGO+ Institute for Health and Care Research,VU University Medical Center, and GGZ inGeest,Amsterdam,The Netherlands. 2. Department of Clinical Chemistry,VU University Medical Center,Amsterdam,The Netherlands.
Abstract
BACKGROUND: Oxidative stress has been implicated in the pathophysiology of major depressive disorder (MDD) and anxiety disorders and may be influenced by antidepressant use. This study investigated the association of oxidative stress, measured by plasma levels of F2-isoprostanes and 8-hydroxy-2'-deoxyguanosine (8-OHdG) reflecting oxidative lipid and DNA damage respectively, with MDD, anxiety disorders and antidepressant use in a large cohort. METHOD: Data was derived from the Netherlands Study of Depression and Anxiety including patients with current (N = 1619) or remitted (N = 610) MDD and/or anxiety disorder(s) (of which N = 704 antidepressant users) and 612 controls. Diagnoses were established with the Composite International Diagnostic Interview. Plasma 8-OHdG and F2-isoprostanes were measured using LC-MS/MS. ANCOVA was performed adjusted for sampling, sociodemographic, health and lifestyle variables. RESULTS: F2-isoprostanes did not differ between controls and patients, or by antidepressant use. Patients with current disorders had lower 8-OHdG (mean 42.1 pmol/l, 95% CI 40.4-43.8) compared to controls (45.0 pmol/l, 95% CI 42.9-47.2; p < 0.001) after adjustment for sampling, sociodemographics and lifestyle, but these differences disappeared after further adjustment for antidepressant use (p = 0.562). Antidepressant users had lower 8-OHdG levels (38.2 pmol/l, 95% CI 36.5-39.9) compared to controls (44.9 pmol/l, 95% CI 43.2-46.6; Cohen's d = 0.21, p < 0.001). Results for 8-OHdG were comparable across disorders (MDD and/or anxiety disorders), and all antidepressant types (SSRIs, TCAs, other antidepressants). CONCLUSION: Contrary to previous findings this large-scale study found no increased oxidative stress in MDD and anxiety disorders. Antidepressant use was associated with lower oxidative DNA damage, suggesting antidepressants may have antioxidant effects.
BACKGROUND: Oxidative stress has been implicated in the pathophysiology of major depressive disorder (MDD) and anxiety disorders and may be influenced by antidepressant use. This study investigated the association of oxidative stress, measured by plasma levels of F2-isoprostanes and 8-hydroxy-2'-deoxyguanosine (8-OHdG) reflecting oxidative lipid and DNA damage respectively, with MDD, anxiety disorders and antidepressant use in a large cohort. METHOD: Data was derived from the Netherlands Study of Depression and Anxiety including patients with current (N = 1619) or remitted (N = 610) MDD and/or anxiety disorder(s) (of which N = 704 antidepressant users) and 612 controls. Diagnoses were established with the Composite International Diagnostic Interview. Plasma 8-OHdG and F2-isoprostanes were measured using LC-MS/MS. ANCOVA was performed adjusted for sampling, sociodemographic, health and lifestyle variables. RESULTS:F2-isoprostanes did not differ between controls and patients, or by antidepressant use. Patients with current disorders had lower 8-OHdG (mean 42.1 pmol/l, 95% CI 40.4-43.8) compared to controls (45.0 pmol/l, 95% CI 42.9-47.2; p < 0.001) after adjustment for sampling, sociodemographics and lifestyle, but these differences disappeared after further adjustment for antidepressant use (p = 0.562). Antidepressant users had lower 8-OHdG levels (38.2 pmol/l, 95% CI 36.5-39.9) compared to controls (44.9 pmol/l, 95% CI 43.2-46.6; Cohen's d = 0.21, p < 0.001). Results for 8-OHdG were comparable across disorders (MDD and/or anxiety disorders), and all antidepressant types (SSRIs, TCAs, other antidepressants). CONCLUSION: Contrary to previous findings this large-scale study found no increased oxidative stress in MDD and anxiety disorders. Antidepressant use was associated with lower oxidative DNA damage, suggesting antidepressants may have antioxidant effects.
Entities:
Keywords:
Anxiety disorders; major depressive disorder; oxidative DNA damage; oxidative lipid damage; oxidative stress
Authors: Lisa R Steenkamp; Christina M Hough; Victor I Reus; Felipe A Jain; Elissa S Epel; S Jill James; Alexandra E Morford; Synthia H Mellon; Owen M Wolkowitz; Daniel Lindqvist Journal: J Affect Disord Date: 2017-05-06 Impact factor: 4.839
Authors: Anders Jorgensen; Kristin Köhler-Forsberg; Trine Henriksen; Allan Weimann; Ivan Brandslund; Christina Ellervik; Henrik E Poulsen; Gitte Moos Knudsen; Vibe G Frokjaer; Martin B Jorgensen Journal: Transl Psychiatry Date: 2022-05-16 Impact factor: 7.989
Authors: Katherine H Shutta; Raji Balasubramanian; Tianyi Huang; Shaili C Jha; Oana A Zeleznik; Candyce H Kroenke; Lesley F Tinker; Jordan W Smoller; Ramon Casanova; Shelley S Tworoger; JoAnn E Manson; Clary B Clish; Kathryn M Rexrode; Susan E Hankinson; Laura D Kubzansky Journal: Psychoneuroendocrinology Date: 2021-09-20 Impact factor: 4.693
Authors: Alessandra das Graças Fedoce; Frederico Ferreira; Robert G Bota; Vicent Bonet-Costa; Patrick Y Sun; Kelvin J A Davies Journal: Free Radic Res Date: 2018-06-04
Authors: Ana Paula Vargas Visentin; Rafael Colombo; Ellen Scotton; Débora Soligo Fracasso; Adriane Ribeiro da Rosa; Catia Santos Branco; Mirian Salvador Journal: Oxid Med Cell Longev Date: 2020-04-14 Impact factor: 6.543
Authors: Paulina Wigner; Ewelina Synowiec; Piotr Czarny; Michal Bijak; Paweł Jóźwiak; Janusz Szemraj; Piotr Gruca; Mariusz Papp; Tomasz Śliwiński Journal: J Cell Mol Med Date: 2020-04-13 Impact factor: 5.310